お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:肥満:競合情勢
市場調査レポート
商品コード
753098

肥満:競合情勢

Obesity: Competitive Landscape to 2026

出版日: | 発行: GlobalData | ページ情報: 英文 50 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=111.33円
肥満:競合情勢
出版日: 2018年10月31日
発行: GlobalData
ページ情報: 英文 50 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、肥満治療薬について調査分析し、パイプラインの評価、治験の評価、商業的な評価、競合情勢分析について、体系的な情報を提供しています。

第1章 序文

第2章 エグゼクティブサマリー

第3章 イントロダクション

第4章 パイプラインの評価

  • パイプラインの概要
  • パイプラインの内訳:地域/国別
  • パイプラインの内訳:分子タイプ・標的別
  • 指定承認
  • 臨床開発中の製品

第5章 治験の評価

  • 治験の概要
  • 治験の主要スポンサー
  • 治験の内訳:地域別
  • 治療分野の見通し
  • 患者登録

第6章 商業的な評価

  • 主な上市製品
  • 現在・将来の企業

第7章 競合情勢分析

  • イベント分類の概要
  • 米国
  • EU5ヶ国
  • 日本
  • カナダ

第8章 付録

目次
Product Code: GDHC017CL

Obesity is a preventable chronic condition, defined as abnormal or excessive fat accumulation characterized by raised body mass index (BMI ≥30), which is a major risk factor for chronic diseases such as cardiovascular diseases (CVD), diabetes, musculoskeletal disorders, and several major cancers.

This report provides an assessment of the pipeline, clinical, and commercial landscape of Obesity. Overall, GlobalData expects that the approval of new long-acting GLP-1R and dual GLP-1R/GCGR agonists, and a novel appetite reducing drug will drive Obesity market growth during the next decade.

Scope

This report combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace. Components of the slide deck include -

  • Pipeline Assessment: regional breakdown, promising late-stage products, early-stage pipeline by molecule type
  • Clinical Trials Assessment: trial breakdown by phase, leading industry and non-industry sponsors, enrollment analytics
  • Commercial Assessment: leading marketed products, current and future players
  • Competitive Landscape Analysis: key market events (2016-2026).

Reasons to buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global Obesity market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Obesity market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1. Preface 2

  • 1.1 Table of Contents 2
  • 1.2 Abbreviations 3
  • 1.3 Related Reports 4

2. Executive Summary 5

  • 2.1 Key Findings 6
  • 2.2 Key Events 7

3. Introduction 8

  • 3.1 Report Scope 9
  • 3.2 Disease Overview and Epidemiology 11

4. Pipeline Assessment 13

  • 4.1 Pipeline Overview 14
  • 4.2 Pipeline Breakdown by Region/Country 16
  • 4.3 Pipeline Breakdown by Molecule Type and Target 17
  • 4.4 Drug Review Designations 18
  • 4.5 Products in Clinical Development 19

5. Clinical Trial Assessment 21

  • 5.1 Clinical Trials Overview 22
  • 5.2 Top Sponsors of Clinical Trials in Obesity 23
  • 5.3 Trial Breakdown by Region 25
  • 5.4 Therapy Area Perspective 26
  • 5.5 Enrollment Analytics 27

6 Commercial Assessment 30

  • 6.1 Leading Marketed Products 31
  • 6.2 Current & Future Players 32

7. Competitive Landscape Analysis (2016-2026) 33

  • 7.1 Events Classification Overview 34
  • 7.2 US 35
  • 7.3 5EU 36
  • 7.4 Japan 37
  • 7.5 China 38

8 Appendix 39

  • 8.1 Sources 40
  • 8.2 Methodology 42
  • 8.3 Key Events Included in the Analysis 43
  • 8.4 About the Authors 45
  • 8.5 About GlobalData 48
  • 8.6 Disclaimer 50
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.